Crispin Blunt
Main Page: Crispin Blunt (Independent - Reigate)Department Debates - View all Crispin Blunt's debates with the Ministry of Justice
(2 years, 10 months ago)
Commons ChamberOn a point of order, Madam Deputy Speaker. On Monday, in answer to my supplementary question during Home Office questions, I believe—I have obtained guidance on the law from a senior lawyer—that the Minister for Crime and Policing most inadvertently misled the House, and I humbly invite him to take this early opportunity to correct the record. The Minister stated that the process for the rescheduling of compounds is that approval is given for a medicine by the Medicines and Healthcare products Regulatory Agency, and advice is then taken from the Advisory Council on the Misuse of Drugs about the rescheduling, as happened with Epidyolex. Nothing in the legislation requires MHRA authorisation for a compound drug to be moved to schedule 2 to 5 under the Misuse of Drugs Regulations 2001.
The effect of the Minister’s statement means that in practice, compounds will largely not be researched to become medicines. That would require market authorisation as, under the apparent new policy, which has so far never been presented to the House, compounds can never escape the rigours and expense of schedule 1. For British scientists that is a particular barrier to the exciting science around the psychedelic class of drugs that is now more easily developed and researched in North America than it is in the UK, where the science began. For those British scientists denied the opportunity to do that research, due to the costs imposed by the scheduling, it is a constant frustration that there is no recent scientific basis to support the scheduling in the first place.
The Minister’s statement was contradictory not only in logic, but also given recent precedent because—ironically, on the basis of the example given by the Minister—market authorisation for Epidyolex was granted two years after cannabis-based medicines and medicinal products as a whole were placed in schedule 2, precisely to facilitate the prescription of non-MHRA approved special medicines.